Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.

Yin Y, Zhang Q, Sun T, Hao C, Wang Z, Yang J, Wang Y, Shi Y, Sun J, Ouyang Q, Su H, Wu J, Gan L, Han M, Gao L, Wang X, Zhao B, Li H, Zhao J, Yang H, Ning F, Tian F, Zhang J, Sun H, Niu Z, Zong H, Zang A, Wang X, Qian X, Wu S, Nie J, He L, Cheng Y, Hao Y, Zhai Y, Li H, Wang J, Wei S, Li M, Liu Y, Guo H, Hu Q, Liu L, Han X, Luo R, Ni M, Tang X, Zhai Z, Ding M, Wang H, Shen P, Wang X, Liu L, Chen W, Liu G, Cai Z, Jiang Z

Open source

DOI
10.1038/s41392-025-02475-6
Published
2025 Dec 18
Container
Signal transduction and targeted therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41392-025-02475-6,
  title = {Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.},
  author = {Yin Y and Zhang Q and Sun T and Hao C and Wang Z and Yang J and Wang Y and Shi Y and Sun J and Ouyang Q and Su H and Wu J and Gan L and Han M and Gao L and Wang X and Zhao B and Li H and Zhao J and Yang H and Ning F and Tian F and Zhang J and Sun H and Niu Z and Zong H and Zang A and Wang X and Qian X and Wu S and Nie J and He L and Cheng Y and Hao Y and Zhai Y and Li H and Wang J and Wei S and Li M and Liu Y and Guo H and Hu Q and Liu L and Han X and Luo R and Ni M and Tang X and Zhai Z and Ding M and Wang H and Shen P and Wang X and Liu L and Chen W and Liu G and Cai Z and Jiang Z},
  year = {2025},
  journal = {Signal transduction and targeted therapy},
  doi = {10.1038/s41392-025-02475-6},
  url = {https://doi.org/10.1038/s41392-025-02475-6}
}

RIS

TY  - JOUR
TI  - Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.
AU  - Yin Y
AU  - Zhang Q
AU  - Sun T
AU  - Hao C
AU  - Wang Z
AU  - Yang J
AU  - Wang Y
AU  - Shi Y
AU  - Sun J
AU  - Ouyang Q
AU  - Su H
AU  - Wu J
AU  - Gan L
AU  - Han M
AU  - Gao L
AU  - Wang X
AU  - Zhao B
AU  - Li H
AU  - Zhao J
AU  - Yang H
AU  - Ning F
AU  - Tian F
AU  - Zhang J
AU  - Sun H
AU  - Niu Z
AU  - Zong H
AU  - Zang A
AU  - Wang X
AU  - Qian X
AU  - Wu S
AU  - Nie J
AU  - He L
AU  - Cheng Y
AU  - Hao Y
AU  - Zhai Y
AU  - Li H
AU  - Wang J
AU  - Wei S
AU  - Li M
AU  - Liu Y
AU  - Guo H
AU  - Hu Q
AU  - Liu L
AU  - Han X
AU  - Luo R
AU  - Ni M
AU  - Tang X
AU  - Zhai Z
AU  - Ding M
AU  - Wang H
AU  - Shen P
AU  - Wang X
AU  - Liu L
AU  - Chen W
AU  - Liu G
AU  - Cai Z
AU  - Jiang Z
PY  - 2025
JO  - Signal transduction and targeted therapy
DO  - 10.1038/s41392-025-02475-6
UR  - https://doi.org/10.1038/s41392-025-02475-6
ER  -

APA

Y, Y., Q, Z., T, S., C, H., Z, W., J, Y., Y, W., Y, S., J, S., Q, O., H, S., J, W., L, G., M, H., L, G., X, W., B, Z., H, L., J, Z., H, Y., F, N., F, T., J, Z., H, S., Z, N., H, Z., A, Z., X, W., X, Q., S, W., J, N., L, H., Y, C., Y, H., Y, Z., H, L., J, W., S, W., M, L., Y, L., H, G., Q, H., L, L., X, H., R, L., M, N., X, T., Z, Z., M, D., H, W., P, S., X, W., L, L., W, C., G, L., Z, C., & Z, J. (2025). Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-025-02475-6

Source records